Moody’s Assigns ‘Junk’ Rating to Grifols Debt
Grifols Receives ‘Junk Bond’ Rating Despite Positive Outlook
Barcelona-based healthcare company Grifols has been assigned a ‘junk bond’ rating of B3 by Moody’s Investors Service,marking a return to credit ratings for the company after a five-month hiatus.
Moody’s withdrew its previous ratings on Grifols in February,citing insufficient facts. The new B3 rating reflects Grifols’ strong market position in the human plasma-derived therapies sector, bolstered by high regulatory barriers, customer loyalty, and significant capital requirements.
The agency also highlighted Grifols’ recent improvements in profitability and liquidity, largely attributed to a €1.3 billion senior secured bond issuance due in 2030. This financing will be used to refinance existing debt maturing in 2025 and reduce reliance on its revolving credit facility.
Despite thes positive developments, Moody’s acknowledges ongoing challenges for Grifols, including €3 billion in debt maturing in 2027 and negative free cash flow generation. As of September 2024, Moody’s adjusted gross leverage stood at 7.2 times, although betterment is anticipated within the next 18 months.Moody’s also recognized positive changes in Grifols’ governance,such as the separation of the roles of chairman and CEO.
The outlook for all of Grifols’ ratings is positive, suggesting potential for upgrades if the company continues to demonstrate progress in addressing its debt burden and improving cash flow.
Grifols Announces Restructuring, aims for Improved Financial Performance
Barcelona, Spain – Spanish pharmaceutical giant Grifols has unveiled a major restructuring plan aimed at bolstering its financial performance and navigating a challenging market landscape. The company announced key changes including a new governance structure with a non-executive chairman and the formation of an Executive Committee.
While Grifols acknowledges its limited track record under this new framework, Moody’s, a leading credit rating agency, projects a positive outlook for the company. Moody’s anticipates moderate single-digit revenue growth over the next 12-18 months, driven by Grifols’ dominant position in the plasma-derived products market.
“Grifols’ leadership in the plasma-derived products market is a key strength,” said a Moody’s analyst.”This, coupled with efficiency programs, cost reductions, and the introduction of higher-margin products, should contribute to improved profitability.”
The restructuring also includes the sale of a 20% stake in Shanghai Raas, a move expected to significantly reduce Grifols’ debt burden. Moody’s forecasts the adjusted leverage ratio to decrease to seven times by the end of 2024 and further down to 6.3 times by the end of 2025.
Despite these positive projections, Grifols anticipates negative free cash flow in 2024 due to high interest costs and capital commitments.Market Reaction
Despite the restructuring announcement and Moody’s optimistic outlook, Grifols’ stock price dipped 1.19% on Wednesday,closing at €9.654 per share. This decline adds to the 37.5% drop the stock has experienced year-to-date.
The market’s reaction suggests investors remain cautious about Grifols’ ability to fully execute its restructuring plan and achieve its financial targets in the face of ongoing economic headwinds.
It truly seems like you’re asking for help understanding some mathematical concepts. please provide me with teh specific concepts or problems you need help with, and I’ll do my best to explain them clearly and help you understand.
Such as, you could ask:
“Can you explain how to find the slope of a line?”
“I’m having trouble understanding quadratic equations. Can you give me an example?”
* “What is the difference between a permutation and a combination?”
the more specific you are, the better I can help! 😄